SEC 13F Intelligence

Managers / Q1 2026

HighVista Strategies LLC

CIK 0001335325 · 200 CLARENDON STREET, 50TH FLOOR, BOSTON, MA, 02116 · 617-406-6500

Reported Value
$362M
Q1 2026
Positions
156
Filings on Record
30
2019–present window
Filed
May 15, 2026
original filing

Summary

Highvista Strategies LLC reported $362M in U.S.-listed holdings across 156 positions for Q1 2026.

Its largest position, DBC, represents 8.5% of the portfolio.

Compared with Q4 2025, the fund opened 35 new positions and exited 24.

Portfolio Metrics

Turnover
+27.9%
vs prior filed quarter
Top-10 Concentration
+27.2%
share of reported value
Largest Position
+8.5%
Invesco Db Commdy Indx Trck
New / Exited
35 / 24
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $116MQ4 ’18Q1 ’19: $123MQ2 ’19: $195MQ3 ’19: $147MQ4 ’19: $132MQ4 ’19Q1 ’20: $108MQ2 ’20: $121MQ3 ’20: $137MQ4 ’20: $157MQ4 ’20Q1 ’21: $135MQ2 ’21: $141MQ3 ’21: $151MQ4 ’21: $126MQ4 ’21Q1 ’22: $157MQ2 ’22: $166MQ3 ’22: $175MQ4 ’22: $168MQ4 ’22Q1 ’23: $123MQ2 ’23: $219MQ3 ’23: $216MQ4 ’23: $276MQ4 ’23Q1 ’24: $280MQ2 ’24: $274MQ3 ’24: $290MQ4 ’24: $269MQ4 ’24Q1 ’25: $260MQ2 ’25: $272MQ3 ’25: $408MQ4 ’25: $388MQ4 ’25Q1 ’26: $362Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 75.6%ADR: 10.8%ETP: 8.5%Other: 4.9%REIT: 0.3%
  • Common Stock · 75.6% · $274M
  • ADR · 10.8% · $39M
  • ETP · 8.5% · $31M
  • Other · 4.9% · $18M
  • REIT · 0.3% · $1M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ORKAORUKA THERAPEUTICS INCNEW+78.9K78.9K+$4M$4M
MLTXMOONLAKE IMMUNOTHERAPEUTICSNEW+194.0K194.0K+$4M$4M
DFTXDEFINIUM THERAPEUTICS INCNEW+185.9K185.9K+$4M$4M
NRIXNURIX THERAPEUTICS INCNEW+226.5K226.5K+$4M$4M
IVAINVENTIVA SANEW+615.7K615.7K+$3M$3M
ERASERASCA INCNEW+181.1K181.1K+$3M$3M
XENEXENON PHARMACEUTICALS INCNEW+49.0K49.0K+$3M$3M
VERAVERA THERAPEUTICS INCNEW+69.2K69.2K+$3M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2026

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1DBCINVESCO DB COMMDY INDX TRCKhistory →UNIT8.45%$31M1.06M
2ABVXABIVAX SAhistory →SPONSORED ADS3.48%$13M113.3K
3PRAXPRAXIS PRECISION MEDICINES Ihistory →COM NEW2.34%$8M26.3K
4COGTCOGENT BIOSCIENCES INChistory →COM2.09%$8M197.1K
5SYRESPYRE THERAPEUTICS INChistory →COM NEW2.04%$7M146.3K
6PCVXVAXCYTE INChistory →COM2.00%$7M124.6K
7RVMDREVOLUTION MEDICINES INChistory →COM1.86%$7M69.3K
8430TERNS PHARMACEUTICALS INChistory →COM1.66%$6M114.3K
9GPCRSTRUCTURE THERAPEUTICS INChistory →SPONSORED ADS1.65%$6M123.9K
10NUVLNUVALENT INChistory →COM1.60%$6M56.6K
11IMVTIMMUNOVANT INChistory →COM1.54%$6M225.1K
12SLNOEURSOLENO THERAPEUTICS INChistory →COM1.53%$6M165.2K
13TYRATYRA BIOSCIENCES INChistory →COM1.39%$5M131.3K
14AMLXAMYLYX PHARMACEUTICALS INChistory →COM1.35%$5M352.1K
15AMZNAMAZON COM INChistory →COM1.29%$5M22.4K
16LBRXLB PHARMACEUTICALS INChistory →COM SHS1.18%$4M173.6K
17RLAYRELAY THERAPEUTICS INChistory →COM1.16%$4M421.9K
18IM8NINSMED INChistory →COM PAR $.011.10%$4M24.3K
19NVDANVIDIA CORPORATIONhistory →COM1.08%$4M22.4K
20ORKAORUKA THERAPEUTICS INChistory →COM1.07%$4M78.9K
21CYTKCYTOKINETICS INChistory →COM NEW1.07%$4M58.6K
22LQDALIQUIDIA CORPORATIONhistory →COM NEW1.04%$4M99.7K
23OCULOCULAR THERAPEUTIX INChistory →COM1.03%$4M441.6K
24TARSTARSUS PHARMACEUTICALS INChistory →COM1.02%$4M52.5K
25BBIOBRIDGEBIO PHARMA INChistory →COM1.02%$4M49.6K
26MLTXMOONLAKE IMMUNOTHERAPEUTICSCLASS A ORD1.00%$4M194.0K
27ARGXARGENX SESPONSORED ADR0.99%$4M4.9K
28PTGXPROTAGONIST THERAPEUTICS INCCOM0.99%$4M33.9K
29PALIPALISADE BIO INCCOM0.98%$4M2.02M
30DFTXDEFINIUM THERAPEUTICS INCCOM SHS0.97%$4M185.9K
31NRIXNURIX THERAPEUTICS INCCOM0.97%$4M226.5K
32AXSMAXSOME THERAPEUTICS INC.COM0.95%$3M20.4K
33IVAINVENTIVA SAADS0.94%$3M615.7K
34DYNDYNE THERAPEUTICS INCCOM0.92%$3M182.9K
35APGEAPOGEE THERAPEUTICS INCCOM0.83%$3M35.8K
36GH RESEARCH PLCORDINARY SHARES0.83%$3M213.2K
37DNTHDIANTHUS THERAPEUTICS INCCOM0.82%$3M35.6K
38MAZEMAZE THERAPEUTICS INCCOM0.82%$3M99.8K
39ERASERASCA INCCOM0.81%$3M181.1K
40EWTXEDGEWISE THERAPEUTICS INCCOM0.80%$3M91.9K
41ELVNENLIVEN THERAPEUTICS INCCOM0.79%$3M73.1K
42XENEXENON PHARMACEUTICALS INCCOM0.79%$3M49.0K
43TCE2CELLDEX THERAPEUTICS INC NEWCOM NEW0.78%$3M89.4K
44VERAVERA THERAPEUTICS INCCL A0.77%$3M69.2K
45PHARVARIS N VCOM0.76%$3M97.9K
46VRDNVIRIDIAN THERAPEUTICS INCCOM0.72%$3M134.2K
47ALKERMES PLCSHS0.71%$3M73.2K
48ALMSALUMIS INCCOM0.69%$2M112.9K
49MSFTMICROSOFT CORPCOM0.66%$2M6.5K
50EYPTEYEPOINT INCCOM NEW0.65%$2M183.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$362M156May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$388M145Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$408M148Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$272M146Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$260M148May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$269M137Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$290M142Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$274M138Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$280M131May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$276M126Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$216M132Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$219M134Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$123M108May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$168M105Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$175M113Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$166M110Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$157M86May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$126M69Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$151M127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$141M116Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$135M125May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$157M117Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$137M113Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$121M100Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$108M65May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$132M119Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$147M126Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$195M108Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$123M112May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$116M113Feb 14, 201913F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 1 additional manager.

  • HighVista Private Capital Management LLC

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.